Nation Clinic is set to launch its first pilot operations in Chelsea and Kensington in Q1 2025, showcasing the full capabilities of its mobile units ahead of broader expansion. The Minimum Viable Product (MVP) is on track for completion by early 2025, enabling live demonstrations and real-world testing.
With a projected five-year revenue of $300 million and an EBITDA of $60 million, Nation Clinic is attracting strong investor interest, particularly from those with expertise in healthcare and franchising. The company is currently preparing for the MVP launch and subsequent fundraising to support its next phase of expansion, with a key focus on entering the US market.
For more information, partnership opportunities, or investment inquiries, please visit
nation.clinic or contact
office@woodford-finance.com.